<DOC>
	<DOC>NCT00638742</DOC>
	<brief_summary>To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.</brief_summary>
	<brief_title>A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.</brief_title>
	<detailed_description>Pharmacokinetics and Safety</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>This study will enroll pediatric and adult subjects with glaucoma or ocular hypertension receiving treatment with latanoprost in either one or both eyes for at least two weeks. The pediatric subjects will be grouped by age (0 to &lt;3 years, 3 to &lt;12 years, 12 to 18 years). Ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the screening visit. History of ocular trauma or surgery in either eye within 14days of the screening visit. Use of continuous wear contact lenses.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Latanoprost Pediatrics Pharmacokinetics Safety</keyword>
</DOC>